Concentrix Named a Leader in Life and Pensions Insurance by Everest Group

   FOR IMMEDIATE RELEASE
   Media Contact: Robert Colbert
   480-696-7074
   [email protected]

Concentrix Named a Leader in Life and Pensions Insurance by Everest Group

FREMONT, CA - Sept. 7, 2016 - Concentrix has been named a Leader in Everest Group's Life and Pensions (L&P) Insurance Business Process Service Provider PEAK Matrix(TM) study. 
"We are honored to be recognized as an L&P leader," said Chris Caldwell, Concentrix President. "Our focus on providing technology and analytics combined with our staff's incredible customer service efforts helped position us as a leader." 

Concentrix Insurance Solutions is one of the largest providers of third party administration services in North America. The insurance vertical has multiple solution and service administration arrangements including flexible administration deployment models of its technology platform, GIAS, as well as Business Process as a Service. GIAS, along with over four decades of industry knowledge, drives three key values to the insurance carrier community: cost savings, process optimization and business transformation. Concentrix provides faster expansion into new markets, access to modern technology, and a robust customer engagement model.

Everest Group's PEAK Matrix focuses on service provider positioning in the Life and Pensions Insurance market, changing market dynamics and assessment of service provider delivery capabilities. Everest Group classifies 30+ L&P service providers based on their performance, experience, ability and knowledge (PEAK) Matrix into three categories of Leaders, Major Contenders and Aspirants. The PEAK Matrix is a framework to assess the relative market success and overall capability of service providers.

About Concentrix
Concentrix, a wholly owned subsidiary of SYNNEX, has operations across six continents, with approximately 125 delivery centers. It has more than 90,000 employees servicing more than 450 clients in more than 40 languages. The company has a large delivery footprint in India, the Philippines, Europe, Asia/Pacific, North America and South America. Concentrix has expertise in 10 industries and offers enhanced capabilities in customer optimization, process optimization, advanced analytics, enabling technologies and non-voice services. Concentrix delivers services by voice, mobile, social and Web chat across multiple geographies. The company operates with a holistic view that includes all customer touchpoints in an omni-channel approach. For information and recent news, visit www.concentrix.com.

About SYNNEX
SYNNEX Corporation (NYSE: SNX), a Fortune 500 corporation, is a leading business process services company, optimizing supply chains and providing outsourced services focused on customer relationship management. SYNNEX distributes a broad range of information technology systems and products, and also provides systems design and integration solutions. Founded in 1980, SYNNEX Corporation operates in 26 countries around the world. Additional information about SYNNEX may be found online at www.synnex.com.

Statements in this release that are forward-looking involve known and unknown risks and uncertainties, which may cause the Company's actual results in future periods to be materially different from any future performance that may be suggested in this release. The Company assumes no obligation to update any forward-looking statements contained in this release.

Copyright 2016 SYNNEX Corporation. All rights reserved. SYNNEX, the SYNNEX Logo, CONCENTRIX and all other SYNNEX company, product and services names and slogans are trademarks or registered trademarks of SYNNEX Corporation. SYNNEX, the SYNNEX Logo and CONCENTRIX Reg. U.S. Pat. & Tm. Off. Other names and marks are the property of their respective owners.

SNX-G

You May Also Be Interested In

• REVIVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Reviva Pharmaceuticals Holdings, Inc. on Behalf of Reviva Stockholders and Encourages Investors to Contact the Firm
• PEP-Therapy and Institut Curie Announce First Patients Dosed in Phase Ib Clinical Trial Evaluating PEP-010 in Ovarian and Pancreatic Cancers
• Stabilization Notice